Fluticasone furoate/umeclidinium/vilanterol - GlaxoSmithKline/Innoviva/Theravance Biopharma

Drug Profile

Fluticasone furoate/umeclidinium/vilanterol - GlaxoSmithKline/Innoviva/Theravance Biopharma

Alternative Names: Closed Triple; Elebrato Ellipta; FF/UMEC/VI; Fluticasone Furoate/Umeclidinium/Vilanterol Trifenatate; Fluticasone furoate/vilanterol/umeclidinium; GSK 2834425; GW 685698/GSK 573719/GW 642444; ICS/LABA/LAMA - GSK; ICS/LAMA/LABA - GSK; TRELEGY ELLIPTA; Trelegy Ellipta; UMEC/VI/FF; Umeclidinium/fluticasone furoate/vilanterol; Umeclidinium/vilanterol/fluticasone furoate; Vilanterol/fluticasone furoate/umeclidinium; Vilanterol/umeclidinium/fluticasone furoate

Latest Information Update: 24 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer GlaxoSmithKline; Innoviva
  • Class Androstadienes; Anti-inflammatories; Antiasthmatics; Benzhydryl compounds; Bronchodilators; Chlorobenzenes; Ethers; Glucocorticoids; Phenols; Quinuclidines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase III Asthma

Most Recent Events

  • 18 Apr 2018 GlaxoSmithKline and Innoviva announces intention to submit regulatory filings in Chronic obstructive pulmonary disease in 2018
  • 18 Apr 2018 Efficacy and adverse events data from a phase III IMPACT trial in Chronic obstructive pulmonary disease released by GlaxoSmithKline and Innoviva
  • 05 Apr 2018 GlaxoSmithKline intends to launch fluticasone furoate/umeclidinium/vilanterol for Chronic obstructive pulmonary disease in Canada in June 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top